Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Erlotinib with neoadjuvant chemotherapy
Sponsor: University of Kansas Medical Center
Collaborators: Genentech, Inc.